This research characterized mucociliary clearance (MCC) in young children with cystic fibrosis (CF).
Fourteen children (5–7 years old) with CF underwent: two baseline MCC measurements (Visits 1 and 2); one MCC measurement approximately 1 year later (Visit 3); and measurements of lung clearance index (LCI), a measure of ventilation inhomogeneity.
Median (range) percent MCC through 60 min (MCC60) was similar on Visits 1 and 2 with 11.0 (0.9–33.7) and 12.8 (2.7–26.8), respectively (p = 0.95), and reproducible (Spearman Rho = 0.69; p = 0.007). Mucociliary clearance did not change significantly over 1 year with median percent MCC60 on Visit 3 [12.8 (3.7–17.6)] similar to Visit 2 (p = 0.58). Lower percent MCC60 on Visit 3 was significantly associated with higher LCI scores on Visit 3 (N = 14; Spearman Rho = −0.56; p = 0.04).
Tests of MCC were reproducible and reliable over a 2-week period and stable over a 1-year period in 5–7-year-old children with CF. Lower MCC values were associated with increased ventilation inhomogeneity. These results suggest that measurements of MCC could be used in short-term clinical trials of interventions designed to modulate MCC and as a new, non-invasive test to evaluate early lung pathology in children with CF.
This is the first study to characterize mucociliary clearance (MCC) in children with cystic fibrosis (CF) who were 5–7 years old.
Measurements of mucociliary clearance were reproducible and reliable over a 2-week period and stable over a 1-year period.
Variability in MCC between children was associated with differences in ventilation homogeneity, such that children with lower MCC values had increased ventilation inhomogeneity.
These results suggest that measurements of MCC could be used in short-term clinical trials of interventions designed to modulate MCC and as a new, non-invasive test to evaluate early lung pathology in children with CF.
Subscribe to Journal
Get full journal access for 1 year
only $9.15 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hodson, M. E., Geddes, D. & Bush, A. Cystic Fibrosis 3rd edn (Hodder Arnold, 2007).
Matsui, H. et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95, 1005–1015 (1998).
Matsui, H. et al. Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces. J. Immunol. 175, 1090–1099 (2005).
Ratjen, F. & Doring, G. Cystic fibrosis. Lancet 361, 681–689 (2003).
Davis, P. B., Drumm, M. & Konstan, M. W. Cystic fibrosis. Am. J. Respir. Crit. Care Med. 154, 1229–1256 (1996).
Laube, B. L. et al. Changes in mucociliary clearance over time on children with cystic fibrosis. Pediatr. Pulmonol. https://doi.org/10.1002/ppul.24858 (2020).
Laube, B. L., Sharpless, G., Benson, J., Carson, K. A. & Mogayzel, P. J. Jr. Mucus removal is impaired in children with cystic fibrosis who have been infected by Pseudomonas aeruginosa. J. Pediatr. 164, 839–845 (2014).
Bennett, W. et al. Multisite comparison of mucociliary and cough clearance measures using standardized methods. J. Aerosol Med. Pulm. Drug Deliv. 26, 157–164 (2013).
Miller, M. R. et al. ATS/ERS Task Force. Standardisation of spirometry. Eur. Respir. J. 26, 319–338 (2005).
Quanjer, P. H. et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur. Respir. J. 40, 1324–1343 (2012).
Brody, A. S. et al. Reproducibility of a scoring system for computed tomography scanning in cystic fibrosis. J. Thorac. Imaging 21, 14–21 (2006).
Robinson, P. D. et al. Consensus statement for inert gas washout measurement using multiple- and single- breath tests. Eur. Respir. J. 41, 507–522 (2013).
Davies, J. C., Cunningham, S., Alton, E. W. & Innes, J. A. Lung clearance index in CF: a sensitive marker of lung disease severity. Thorax 63, 96–97 (2008).
Aurora, P. et al. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 171, 249–256 (2005).
Schaedel, C. et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr. Pulmonol. 33, 483–491 (2002).
Kraemer, R., Blum, A., Schibler, A., Ammann, R. A. & Gallati, S. Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 171, 371–378 (2005).
Gustafsson, P. M., De Jong, P. A., Tiddens, H. A. & Lindblad, A. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax 63, 129–134 (2008).
Cutting, G. R. Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann. NY Acad. Sci. 1214, 57–69 (2010).
Chalmers, J. D., Fleming, G. B., Hill, A. T. & Kilpatrick, D. C. Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: a review and meta-analysis. Glycobiology 21, 271–282 (2011).
Corvol, H., Cutting, G. R., Drumm, M. L., Knowles, M. R. & Strug, L. J. Genome-wide association meta-analysis in ~6,400 CF patients confirms previous findings and identifies new loci contributing to variation in lung disease. Pediatr. Pulmonol. 49, 271–272 (2014).
Kesimer, M. et al. Molecular organization of the mucins and glycocalyx underlying mucus transport over mucosal surfaces of the airways. Mucosal Immunol. 6, 379–392 (2013).
Wright, F. A. et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat. Genet. 43, 539–546 (2011).
Blue, E. et al. Variation in cilia protein genes and progression of lung disease in cystic fibrosis. Ann. Am. Thorac. Soc. 15, 440–448 (2018).
Emond, M. J. et al. Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat. Genet. 44, 886–889 (2013).
Evans, C. M. et al. The polymeric mucin Muc5ac is required for allergic airway hyperreactivity. Nat. Commun. 6, 6281 (2015).
Roy, M. G. et al. Muc5b is required for airway defense. Nature 505, 412–416 (2014).
Stock, C. J. et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 68, 436–441 (2013).
Kamio, K. et al. Promoter analysis and aberrant expression of the MUC5B gene in diffuse panbronchiolitis. Am. J. Respir. Crit. Care Med 171, 949–957 (2005).
Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).
Mayer-Hamblett, N. et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am. J. Respir. Crit. Care Med. 175, 822–828 (2007).
Laube, B. L., Carson, K. A., Sharpless, G., Paulin, L. M. & Hansel, N. N. Mucociliary clearance in former tobacco smokers with both chronic obstructive pulmonary disease and chronic bronchitis and the effect of Roflumilast. J. Aerosol Med. Pulm. Drug Deliv. 32, 189–199 (2019).
Newman, S. et al. Standardization of techniques for using planar (2D) imaging for aerosol deposition assessment of orally inhaled products. J. Aerosol Med. Pulm. Drug Deliv. 25, S10–S28 (2012).
Fleiss, J. L. In The Design and Analysis of Clinical Experiments 264–281 (Wiley, 1999).
Henke, M. O. et al. MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation. Am. J. Respir. Crit. Care Med. 175, 816–821 (2007).
Henderson, A. G. et al. Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. J. Clin. Investig. 124, 3047–3060 (2014).
The authors wish to thank Douglas Walker for performing MBW and induced sputum tests and lung function procedures and Jane Benson, MD and Emily Dunn, MD for scoring HCRT scans. Douglas Walker, Jane Benson, and Emily Dunn were supported by the NIH (R01 HL129925). We also wish to thank Andrew Lipton, MD, Chief, Pediatric Pulmonology, the Walter Reed National Military Medical Center and his clinical coordinators, Funmilola Crawford and Jane Jacknewitz-Woolard, and Dr. Edith Zemanick, MD, Associate Professor, Pediatrics, University of Colorado Denver and her clinical coordinators, Dana Coyle and Meg Anthony, for their referrals to this study. B.L.L., K.A.C., J.M.C., P.J.M., P.L.Z., C.M.E. and G.S. were supported by the NIH (R01 HL129925). B.L.L. and K.A.C. were also supported by the Johns Hopkins Institute for Clinical and Translational Research, which was funded in part by the NIH (UL1 TR001079). C.M.E. and V.L.R. were supported by the NIH (R01 HL130938, R01 HL080396) and by the Cystic Fibrosis Foundation (CFF EVANS18I0).
The authors declare no competing interests.
Written, informed consent was obtained from parents, or guardians, of children who participated in the study. The study was approved by the Johns Hopkins Institutional Review Board.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Laube, B.L., Carson, K.A., Evans, C.M. et al. Characterizing mucociliary clearance in young children with cystic fibrosis. Pediatr Res (2021). https://doi.org/10.1038/s41390-021-01453-2